|
Baseline (June 2011)
|
|
No. of children infected/examined
|
91/142
|
150/187
| |
88/141
|
85/105
|
68/83
| |
|
Prevalence (95 % CI)
|
64.1 % (55.9-71.5)
|
80.2 % (73.9-85.3)
|
0.001
|
62.4 % (54.2-69.9)
|
80.9 % (72.4-87.3)
|
81.9 % (62.3-88.7)
|
0.001
|
|
Numbers of infected subject treated with PZQ
|
91
|
146
| |
88
|
83
|
66
| |
|
GM egg count/10 ml of urine (95 % CI)
|
177.0 (123.4-253.8)
|
544.1 (421.4-702.6)
|
0.001
|
238.9 (164.4-347.3)
|
455.6 (313–662.9)
|
438.7 (299.1-643.3)
|
<0.001
|
|
Treatment (August 2011)
|
|
Follow-up efficacy of PZQ 5 weeks post treatment (in September 2011)
|
|
No. of children infected/examined
|
3/142
|
12/183
| |
6/141
|
8/103
|
1/81
| |
|
Prevalence (95 % CI)
|
2.1 % (0.7-6)
|
6.5 % (3.7-10.9)
|
0.080
|
4.2 % (1.9-8.9)
|
7.7 % (3.9-14.4)
|
1.2 % (0.2-6.7)
|
0.200
|
|
No. of infected treated examined
|
91
|
146
| |
88
|
83
|
66
| |
|
No of children cured (CR in %)
|
88 (96.7 %)
|
134 (91.8 %)
|
0.7
|
82 (93.2 %)
|
76 (91.7 %)
|
64 (96.9 %)
|
0.5
|
|
GM egg count/10 ml of urine (95 % CI)
|
15.7 (3.7-65.4)
|
55.8 (25.5-112.9)
|
0.06
|
26.5 (8–87.7)
|
67.0 (26.9-166.5)
|
25.0
|
0.109
|
|
ERR in %
|
91.1 %
|
89.7 %
|
0.99
|
88.9 %
|
85.3 %
|
94.3 %
|
0.99
|
|
Reinfection after treatment (September to November 2011)
|
|
Follow-up reinfection 2 to 3 months after transmission period in February and March 2012
|
|
No. of children infected/examined
|
11/142
|
34/183
| |
22/141
|
14/103
|
9//81
| |
|
Prevalence (95 % CI)
|
7.7 % (4.3-13.3)
|
18.6 % (13.1-24.8)
|
0.010
|
15.6 % (10.5-22.5)
|
13.6 % (8.2-21.5)
|
11.1 % (5.9-19.8)
|
0.486
|
|
GM egg count/10 ml of urine (95 % CI)
|
37.4 (37.4-12.38)
|
52.4 (25.2-109.2)
|
0.012
|
73.1 (31.8-168.3)
|
27.8 (9.4-82.4)
|
38.6 (5.6-263.7)
|
0.307
|
|
No. Of children re-infected/surveyed
|
8/139
|
22/173
| |
16/135
|
8/96
|
6/81
| |
|
Reinfection rate (95 % CI)
|
5.7 % (2.9-10.9)
|
12.7 % (8.5-18.5)
|
0.001
|
11.8 % (7.4-18.4)
|
8.3 % (4.3-15.6)
|
7.4 % (3.4-15.2)
|
0.400
|
